---
title: "RBC Capital Sticks to Its Hold Rating for Agios Pharma (AGIO)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284859883.md"
description: "RBC Capital has maintained a Hold rating on Agios Pharma (AGIO) with a price target of $28.00, while the shares closed at $28.05. Analyst Luca Issi has an average return of -3.4% and a 36.90% success rate. J.P. Morgan also issued a Hold rating, while Truist Financial maintained a Buy rating on the stock."
datetime: "2026-05-01T02:16:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284859883.md)
  - [en](https://longbridge.com/en/news/284859883.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284859883.md)
---

# RBC Capital Sticks to Its Hold Rating for Agios Pharma (AGIO)

In a report released on April 29, Luca Issi from RBC Capital maintained a Hold rating on Agios Pharma, with a price target of $28.00. The company’s shares closed yesterday at $28.05.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Issi is an analyst with an average return of \-3.4% and a 36.90% success rate. Issi covers the Healthcare sector, focusing on stocks such as Amgen, Wave Life Sciences, and Ascendis Pharma.

In addition to RBC Capital, Agios Pharma also received a Hold from J.P. Morgan’s Tessa Romero in a report issued on April 20. However, yesterday, Truist Financial maintained a Buy rating on Agios Pharma (NASDAQ: AGIO).

### Related Stocks

- [AGIO.US](https://longbridge.com/en/quote/AGIO.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [WVE.US](https://longbridge.com/en/quote/WVE.US.md)
- [ASND.US](https://longbridge.com/en/quote/ASND.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [TFC.US](https://longbridge.com/en/quote/TFC.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)

## Related News & Research

- [Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances](https://longbridge.com/en/news/286947828.md)
- [47,414 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by State of New Jersey Common Pension Fund D](https://longbridge.com/en/news/285910345.md)
- [Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference | RIGL Stock News](https://longbridge.com/en/news/286413210.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [How Strong UGN-103 Phase 3 Durability Data At UroGen Pharma (URGN) Has Changed Its Investment Story](https://longbridge.com/en/news/286658162.md)